BiotechTube

[203Pb]VMT-α-NET + [212Pb]VMT-α-NET

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumors Unresectable

Conditions

Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma

Trial Timeline

Sep 27, 2023 → Dec 26, 2029

NCT ID
NCT05636618

About [203Pb]VMT-α-NET + [212Pb]VMT-α-NET

[203Pb]VMT-α-NET + [212Pb]VMT-α-NET is a phase 1/2 stage product being developed by Perspective Therapeutics for Neuroendocrine Tumors Unresectable. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05636618. Target conditions include Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05636618Phase 1/2Recruiting

Competing Products

20 competing products in Neuroendocrine Tumors Unresectable

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
25
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
25
LenvatinibEisaiPhase 2
52
AbemaciclibEli LillyPhase 2
52
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
77
OlaparibAstraZenecaPhase 2
52
AvelumabMerckPhase 1/2
41
PembrolizumabMerckPhase 2
52
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Pembrolizumab InjectionMerckPhase 2
52
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
52
Pembrolizumab + LenvatinibMerckPhase 2
52
AvelumabMerckPhase 2
52
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
52
MK-0646MerckPhase 2
52
Lanreotide + PembrolizumabMerckPhase 1/2
41

Other Products from Perspective Therapeutics

[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPhase 1/2
33
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Phase 1/2
33
[203Pb]VMT-α-NETPhase 1
25
[212Pb] VMT-α-NETPhase 1
25
[203Pb]VMT01 + [68Ga]VMT02Phase 1
25